A study by the research team led by Prof. Kai Kappert, published in Cellular Signalling, investigates the role of pro-inflammatory cytokines in the regulation of protein tyrosine phosphatases (PTPs) and insulin signaling pathways in murine skeletal muscle cells (C2C12). The research shows how tumor necrosis factor (TNF), interleukin-1? (IL-1?), and interleukin-6 (IL-6) influence the expression and activity of PTPN1 (PTP1B) and PTPN2 (TCTP), which are considered negative regulators of the insulin signaling pathway. The study demonstrates that the cytokines induce different kinetics and expression patterns of PTPs and insulin signaling molecules without significantly impairing insulin action. Pharmacological inhibition with sodium orthovanadate and siRNA-mediated knockdown of PTPN1 and PTPN2 confirmed that PTPs inhibit insulin signal transduction. However, the knockdown showed only minor effects on the insulin signaling pathway, as other PTPs were regulated compensatorily. The results highlight the complex interplay between cytokines, PTPs, and metabolic signaling pathways. These findings are crucial for the development of new therapeutic approaches for inflammatory diseases such as type 2 diabetes… 

New York, August 4, 2025 – With an aging population in the US, chronic and rare diseases are gaining importance, especially among older adults. Over 30 million Americans suffer from rare diseases, many without approved therapies. The Trump administration's "Make America Healthy Again" initiative aims to improve access to treatments and accelerate medical innovation. Soligenix Inc. (NASDAQ: SNGX) is making progress with its HyBryte™ platform, a novel therapy for cutaneous T-cell lymphoma (CTCL), a rare skin cancer that primarily affects older individuals. The successful US production of HyBryte™'s active ingredient underscores Soligenix's commitment to innovative solutions. CTCL, a rare form of non-Hodgkin lymphoma, affects over 40,000 patients worldwide and has no cure. The most common subtype, mycosis fungoides, accounts for about 90% of cases. There is no approved first-line therapy for early stages, highlighting the need for new treatment options. The global… 

Shenzhen, China, August 4, 2025 – Pulsecare Medical, a leader in cardiovascular intervention technology development, has received market approval from the China National Medical Products Administration (NMPA) for its NxPFA™ system. This world's first nanosecond pulsed field ablation (ns-PFA) system marks the beginning of the so-called PFA 3.0 era. It utilizes high-voltage nanosecond pulses for pulmonary vein isolation (PVI) in treating atrial fibrillation (AF), offering advantages over previous microsecond PFA systems. The NxPFA™ system, comprising the MaviPulse™ console and InteShot™ basket catheter, reduces neuromuscular stimulation, enables procedures under conscious sedation, and minimizes risks such as stroke or kidney damage through lower gas formation and erythrocyte damage. The system was clinically validated in the SCENA-AF study involving 166 patients with paroxysmal atrial fibrillation. Results show a 100% acute PVI success rate, an 88.27% one-year treatment success rate, no device-related serious adverse events, and over 92.8% of procedures performed under conscious sedation with high patient tolerance. The approval represents a milestone for Pulsecare Medical…